Amylx Pharmaceuticals Inc vs Herbalife Nutrition Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.1× Herbalife Nutrition Ltd's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | HLF | |
|---|---|---|
Market Cap | $2.64B | $1.23B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $19.96 |
52-Week Low | $7.82 | $7.75 |
Enterprise Value | $2.39B | $3.06B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
Herbalife (HLF) trades at $11.695, up 1.52% on the day, with a bearish technical outlook per moving averages. The company reported Q2 2026 net sales of $1.3 billion, a 5.4% year-over-year increase, though EPS of $0.51 missed estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24. Positive news includes being named to TIME's America's Best Companies 2026 list, but a planned CFO transition in December 2026 introduces uncertainty.
The outlook is mixed; strong sales growth and low valuation metrics offer potential upside, but recent earnings misses, a high debt load, and negative shareholder equity pose significant risks. Analyst consensus leans bullish with 53.84% buy ratings, yet the stock faces headwinds from competitive pressures and margin volatility.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →